FDA issues vision loss warning for GLP-1 drugs
The Food and Drug Administration issued a new warning on Monday about the risk of vision loss related to popular GLP-1 weight loss and diabetes drugs.
Health officials say drugs like Eli Lilly’s Zepbound and Ozempic by Novo Nordisk must add a warning label about the rare disease, which can cause blurred vision or blindness.
The FDA says anyone experiencing such problems should contact a health care professional immediately.
While the condition is permanent with no known treatment, experts say it occurs in only a tiny fraction of patients.
Watch PBS News for daily, breaking and live news, plus special coverage. We are home to PBS News Hour, ranked the most credible and objective TV news show.
Sign up for Here’s The Deal with Lisa Desjardins: https://to.pbs.org/41q6E8i
Subscribe for exclusive content in our newsletters: https://www.pbs.org/newshour/subscribe
PBS News podcasts: https://www.pbs.org/newshour/podcasts
Stream your PBS favorites with the PBS app: https://to.pbs.org/2Jb8twG
Find more from PBS News at https://www.pbs.org/newshour
Subscribe to our YouTube channel: https://bit.ly/2HfsCD6
Follow us:
TikTok: https://www.tiktok.com/@pbsnews
X: http://www.twitter.com/newshour
Instagram: http://www.instagram.com/newshour
Facebook: https://www.facebook.com/newshour/
